Differences in Rate of Decline in CT-defined Skeletal Muscle Mass and Physical Performance in Patients With Advanced Non-small Cell Lung Cancer Receiving Chemotherapy and Targeted Therapy/Immunotherapy, Before and After Treatment.
Prince of Songkla University
240 participants
Aug 1, 2022
OBSERVATIONAL
Conditions
Summary
Lung cancer is a common disease leading to 18 % of cancer deaths worldwide. Despite various improvement in treatment, there still remains low 5-year survival rate of 10-20 % in advanced lung cancer patients. Skeletal muscle mass and physical performance have been shown to effect overall survival and prognosis in lung cancer. This research focuses on effects of different treatment of lung cancer such as chemotherapy, targeted therapy and immunotherapy on skeletal muscle mass and physical performance.
Eligibility
Inclusion Criteria3
- Age \>18years old,
- Stage IIIB and IIIC (if patients are treated with TKI/IO), and Stage IV non-small cell lung cancer patients confirmed by histopathology.
- Patients should be either on chemotherapy, molecular targeted therapy or immunotherapy.
Exclusion Criteria5
- Unable to perform CT scan due to various reasons.
- Patients with metastatic disease at L3 vertebral level.
- If unable to perform SPPB test due to physical disability or patient's refusal.
- Patients with known other primary malignancies. 5 . Patients who have underwent definitive surgery.
- \. Pregnant patients. 7. Patients with physical deformities/neurological deficits which restricts their physical movements.
Interventions
Chemotherapy drug as prescribed by primary treating physician
Targeted agents as prescribed by primary treating physician
Immunotherapy as prescribed by primary treating physician
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06326086